Sueblinvong T - Search Results

1

Establishment, characterization and downstream application of primary ovarian cancer cells derived from solid tumors.

Sueblinvong T, Ghebre R, Iizuka Y, Pambuccian SE, Isaksson Vogel R, Skubitz AP, Bazzaro M. Sueblinvong T, et al. PLoS One. 2012;7(11):e50519. doi: 10.1371/journal.pone.0050519. Epub 2012 Nov 30. PLoS One. 2012. PMID: 23226302 Free PMC article.

2

Method for obtaining primary ovarian cancer cells from solid specimens.

Pribyl LJ, Coughlin KA, Sueblinvong T, Shields K, Iizuka Y, Downs LS, Ghebre RG, Bazzaro M. Pribyl LJ, et al. Among authors: sueblinvong t. J Vis Exp. 2014 Feb 4;(84):e51581. doi: 10.3791/51581. J Vis Exp. 2014. PMID: 24562185 Free PMC article.

3

Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells.

Anchoori RK, Khan SR, Sueblinvong T, Felthauser A, Iizuka Y, Gavioli R, Destro F, Isaksson Vogel R, Peng S, Roden RB, Bazzaro M. Anchoori RK, et al. Among authors: sueblinvong t. PLoS One. 2011;6(8):e23888. doi: 10.1371/journal.pone.0023888. Epub 2011 Aug 31. PLoS One. 2011. PMID: 21909374 Free PMC article.

4

Water-fat MRI for assessing changes in bone marrow composition due to radiation and chemotherapy in gynecologic cancer patients.

Bolan PJ, Arentsen L, Sueblinvong T, Zhang Y, Moeller S, Carter JS, Downs LS, Ghebre R, Yee D, Froelich J, Hui S. Bolan PJ, et al. Among authors: sueblinvong t. J Magn Reson Imaging. 2013 Dec;38(6):1578-84. doi: 10.1002/jmri.24071. Epub 2013 Feb 28. J Magn Reson Imaging. 2013. PMID: 23450703 Free PMC article. Clinical Trial.

5

A phase I feasibility study of multi-modality imaging assessing rapid expansion of marrow fat and decreased bone mineral density in cancer patients.

Hui SK, Arentsen L, Sueblinvong T, Brown K, Bolan P, Ghebre RG, Downs L, Shanley R, Hansen KE, Minenko AG, Takhashi Y, Yagi M, Zhang Y, Geller M, Reynolds M, Lee CK, Blaes AH, Allen S, Zobel BB, Le C, Froelich J, Rosen C, Yee D. Hui SK, et al. Among authors: sueblinvong t. Bone. 2015 Apr;73:90-7. doi: 10.1016/j.bone.2014.12.014. Epub 2014 Dec 20. Bone. 2015. PMID: 25536285 Free PMC article. Clinical Trial.

6

Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer.

Argenta PA, Um I, Kay C, Harrison D, Faratian D, Sueblinvong T, Geller MA, Langdon SP. Argenta PA, et al. Among authors: sueblinvong t. Gynecol Oncol. 2013 Nov;131(2):368-73. doi: 10.1016/j.ygyno.2013.07.099. Epub 2013 Jul 30. Gynecol Oncol. 2013. PMID: 23911795 Clinical Trial.

7

Ovarian cancer: risks.

Sueblinvong T, Carney ME. Sueblinvong T, et al. Hawaii Med J. 2009 Mar;68(2):40-6. Hawaii Med J. 2009. PMID: 19385377 Review. No abstract available.

8

Current understanding of risk factors for ovarian cancer.

Sueblinvong T, Carney ME. Sueblinvong T, et al. Curr Treat Options Oncol. 2009 Apr;10(1-2):67-81. doi: 10.1007/s11864-009-0108-2. Epub 2009 Jul 15. Curr Treat Options Oncol. 2009. PMID: 19603272 Review.

9

Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study.

Argenta PA, Sueblinvong T, Geller MA, Jonson AL, Downs LS Jr, Carson LF, Ivy JJ, Judson PL. Argenta PA, et al. Among authors: sueblinvong t. Gynecol Oncol. 2013 Apr;129(1):81-5. doi: 10.1016/j.ygyno.2013.01.010. Epub 2013 Jan 23. Gynecol Oncol. 2013. PMID: 23352917

10

Solitary fibrous tumors arising from the female pelvis.

Sueblinvong T, Judson PL, Downs LS Jr, Argenta PA. Sueblinvong T, et al. Obstet Gynecol. 2011 Aug;118(2 Pt 2):470-474. doi: 10.1097/AOG.0b013e31821b2037. Obstet Gynecol. 2011. PMID: 21768857

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters